Cargando…

Efficacy of an Immunotherapy Combining Immunogenic Chimeric Protein Plus Adjuvant and Amphotericin B against Murine Visceral Leishmaniasis

SIMPLE SUMMARY: Visceral leishmaniasis is a tropical neglected disease caused by infection with Leishmania parasites. There are no human vaccines and the current drug treatments for infected patients are hampered by toxicity and the development of resistance. In our study, we have used an immunother...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vale, Danniele L., Freitas, Camila S., Martins, Vívian T., Moreira, Gabriel J. L., Machado, Amanda S., Ramos, Fernanda F., Pereira, Isabela A. G., Bandeira, Raquel S., de Jesus, Marcelo M., Tavares, Grasiele S. V., Ludolf, Fernanda, Chávez-Fumagalli, Miguel A., Galdino, Alexsandro S., Fujiwara, Ricardo T., Bueno, Lílian L., Roatt, Bruno M., Christodoulides, Myron, Coelho, Eduardo A. F., Lage, Daniela P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295016/ https://www.ncbi.nlm.nih.gov/pubmed/37372136 http://dx.doi.org/10.3390/biology12060851

Ejemplares similares

Immunotherapy Using Immunogenic Mimotopes Selected by Phage Display plus Amphotericin B Inducing a Therapeutic Response in Mice Infected with Leishmania amazonensis
por: Soyer, Tauane G., et al.
Publicado: (2023)

A Recombinant Chimeric Protein-Based Vaccine Containing T-Cell Epitopes from Amastigote Proteins and Combined with Distinct Adjuvants, Induces Immunogenicity and Protection against Leishmania infantum Infection
por: Lage, Daniela P., et al.
Publicado: (2022)

ChimLeish, a new recombinant chimeric protein evaluated as a diagnostic and prognostic marker for visceral leishmaniasis and human immunodeficiency virus coinfection
por: Galvani, Nathalia C., et al.
Publicado: (2021)

A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection
por: Lage, Daniela P., et al.
Publicado: (2020)

B-Cell Epitopes-Based Chimeric Protein from SARS-CoV-2 N and S Proteins Is Recognized by Specific Antibodies in Serum and Urine Samples from Patients
por: Ramos, Fernanda F., et al.
Publicado: (2023)

A clioquinol-containing Pluronic(®) F127 polymeric micelle system is effective in the treatment of visceral leishmaniasis in a murine model
por: Tavares, Grasiele S.V., et al.
Publicado: (2020)

Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis
por: Costa, Rafaella R., et al.
Publicado: (2021)

Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis
por: Lage, Daniela P., et al.
Publicado: (2020)

Immunoproteomics and phage display in the context of leishmaniasis complexity
por: Ludolf, Fernanda, et al.
Publicado: (2023)

Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis
por: Freitas, Camila S., et al.
Publicado: (2020)

In vitro and in vivo antileishmanial activity of β-acetyl-digitoxin, a cardenolide of Digitalis lanata potentially useful to treat visceral leishmaniasis
por: Freitas, Camila S., et al.
Publicado: (2021)

Amphotericin B Formulations and Other Drugs for Visceral Leishmaniasis
por: Berman, Jonathan
Publicado: (2015)

Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2021)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B
por: Morizot, Gloria, et al.
Publicado: (2016)

Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
por: Hasnain, Md Golam, et al.
Publicado: (2018)

Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2017)

Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis
por: Shahnaz, Gul, et al.
Publicado: (2017)

Transcriptional blood signatures for active and amphotericin B treated visceral leishmaniasis in India
por: Fakiola, Michaela, et al.
Publicado: (2019)

A urine-based ELISA with recombinant non-glycosylated SARS-CoV-2 spike protein for detecting anti-SARS-CoV-2 spike antibodies
por: Ramos, Fernanda F., et al.
Publicado: (2023)

A rapid diagnostic test for human Visceral Leishmaniasis using novel Leishmania antigens in a Laser Direct-Write Lateral Flow Device
por: Humbert, Maria Victoria, et al.
Publicado: (2019)

Liposomal Amphotericin B and Leishmaniasis: Dose and Response
por: Sundar, Shyam, et al.
Publicado: (2010)

Ocular Leishmaniasis Treated by Intralesional Amphotericin B
por: Nikandish, Malihe, et al.
Publicado: (2016)

Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis
por: Ren, Danfeng, et al.
Publicado: (2021)

An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasis
por: Ribeiro, Tatiana G, et al.
Publicado: (2014)

Chimeric Vaccines Designed by Immunoinformatics-Activated Polyfunctional and Memory T cells that Trigger Protection against Experimental Visceral Leishmaniasis
por: De Brito, Rory Cristiane Fortes, et al.
Publicado: (2020)

Liposomal amphotericin B as a treatment for human leishmaniasis
por: Balasegaram, Manica, et al.
Publicado: (2012)

Efficacy of Intralesional Amphotericin B for the Treatment of Cutaneous Leishmaniasis
por: Goyonlo, Vahid Mashayekhi, et al.
Publicado: (2014)

Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B
por: Ubals, Maria, et al.
Publicado: (2021)

Small Myristoylated Protein-3, Identified as a Potential Virulence Factor in Leishmania amazonensis, Proves to be a Protective Antigen against Visceral Leishmaniasis
por: Oliveira, Marcelo P., et al.
Publicado: (2018)

Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies
por: Mudavath, Shyam Lal, et al.
Publicado: (2014)

Relapse of visceral leishmaniasis in an HIV-infected patient successfully treated with a combination of miltefosine and amphotericin B
por: McQuarrie, Shauna, et al.
Publicado: (2015)

Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis
por: Riezk, Alaa, et al.
Publicado: (2020)

Detecting anti–SARS-CoV-2 antibodies in urine samples: A noninvasive and sensitive way to assay COVID-19 immune conversion
por: Ludolf, Fernanda, et al.
Publicado: (2022)

Treatment of mucosal leishmaniasis with amphotericin B lipid complex (ABLC)
por: Tuon, Felipe Francisco, et al.
Publicado: (2018)

Disseminated tegumentary leishmaniasis refractory to liposomal amphotericin B treatment
por: Borges, Ana Flávia, et al.
Publicado: (2021)

First case of pulmonary tuberculosis and visceral leishmaniasis coinfection successfully treated with antituberculosis drug and liposomal amphotericin B
por: Hasnain, Md Golam, et al.
Publicado: (2014)

Post Kala-Azar Dermal Leishmaniasis following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) for Primary Visceral Leishmaniasis in Bihar, India
por: Burza, Sakib, et al.
Publicado: (2014)

Auricular leishmaniasis in a child successfully treated with intralesional amphotericin B
por: Diociaiuti, Andrea, et al.
Publicado: (2022)

Leishmania infantum β-Tubulin Identified by Reverse Engineering Technology through Phage Display Applied as Theranostic Marker for Human Visceral Leishmaniasis
por: Costa, Lourena E., et al.
Publicado: (2019)

Effectiveness and Safety of Short Course Liposomal Amphotericin B (AmBisome) as First Line Treatment for Visceral Leishmaniasis in Bangladesh
por: Lucero, Emiliano, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_m49mb015aha290g0ptefqk1068